Loomis Sayles & Co. L P trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 31.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 417,208 shares of the biopharmaceutical company's stock after selling 195,158 shares during the period. Loomis Sayles & Co. L P owned about 0.73% of Agios Pharmaceuticals worth $13,709,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also added to or reduced their stakes in AGIO. Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. bought a new stake in Agios Pharmaceuticals during the fourth quarter valued at about $53,000. KBC Group NV lifted its position in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 611 shares during the last quarter. Quest Partners LLC grew its position in shares of Agios Pharmaceuticals by 139.6% in the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company's stock worth $98,000 after buying an additional 1,283 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $146,000.
Insider Activity
In related news, insider Tsveta Milanova sold 2,804 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company's stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.93% of the company's stock.
Agios Pharmaceuticals Stock Performance
NASDAQ AGIO traded up $1.00 during mid-day trading on Wednesday, reaching $28.40. 325,675 shares of the stock were exchanged, compared to its average volume of 702,040. Agios Pharmaceuticals, Inc. has a 1 year low of $26.66 and a 1 year high of $62.58. The business's 50 day moving average is $32.99 and its 200-day moving average is $40.58. The company has a market capitalization of $1.63 billion, a P/E ratio of 2.50 and a beta of 0.90.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.
Analysts Set New Price Targets
AGIO has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. Finally, Scotiabank boosted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, Agios Pharmaceuticals has a consensus rating of "Hold" and an average price target of $56.57.
Read Our Latest Stock Analysis on Agios Pharmaceuticals
About Agios Pharmaceuticals
(
Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Read More
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
